MARKET

ARMP

ARMP

Armata Pharmctcl
AMEX
2.370
+0.180
+8.22%
Closed 16:00 12/01 EST
OPEN
2.230
PREV CLOSE
2.190
HIGH
2.390
LOW
2.140
VOLUME
11.03K
TURNOVER
0
52 WEEK HIGH
5.26
52 WEEK LOW
0.8311
MARKET CAP
85.67M
P/E (TTM)
-1.4365
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at ARMP last week (1120-1124)?
Weekly Report · 6d ago
Weekly Report: what happened at ARMP last week (1113-1117)?
Weekly Report · 11/20 10:06
Armata Pharmctcl: Securities to be offered to employees in employee benefit plans
Press release · 11/16 05:11
Armata Pharmctcl: Quarterly report
Press release · 11/15 17:10
Armata Pharmaceuticals: A Promising Buy Based on Therapeutic Pipeline, Financial Stability, and Strategic Partnerships
TipRanks · 11/15 11:46
Robust Advancements and Strategic Planning: Key Drivers for Armata Pharmaceuticals’ Buy Rating
TipRanks · 11/15 11:22
Armata Pharmctcl: Current report
Press release · 11/15 01:13
Armata Pharmaceuticals GAAP EPS of -$0.86, revenue of $1.2M
Armata pharmaceuticals reports q3 gaap eps of -$0.86, revenue of $1.2m. Armata's q3 results were better than expected. The company posted a loss of $2.2 million in the third quarter. The stock closed at -0.8% on tuesday.
Seeking Alpha · 11/14 22:11
More
About ARMP
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. It has developed care therapies, including the multidrug-resistant or superbug strains of bacteria. The Company is a developer of phage therapeutics, which are positioned to address the growing worldwide threat of antibiotic-resistant bacterial infections. It is developing and advancing its lead clinical phage candidate for Pseudomonas aeruginosa. The Company is also developing a phage product candidate for Staphylococcus aureus for the treatment of staphylococcus aureus bacteremia. It has phage development to target other indications, including non-cystic fibrosis bronchiectasis, prosthetic joint infections and hospitalized pneumonia. Its product candidates are AP-PA02, AP-PA03 and AP-SA02.

Webull offers Armata Pharmaceuticals Inc stock information, including AMEX: ARMP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARMP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ARMP stock methods without spending real money on the virtual paper trading platform.